CN102470105B - 持续释放药物载体组合物 - Google Patents

持续释放药物载体组合物 Download PDF

Info

Publication number
CN102470105B
CN102470105B CN201080034537.XA CN201080034537A CN102470105B CN 102470105 B CN102470105 B CN 102470105B CN 201080034537 A CN201080034537 A CN 201080034537A CN 102470105 B CN102470105 B CN 102470105B
Authority
CN
China
Prior art keywords
another embodiment
lipid
fatty acid
composition
matrix composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201080034537.XA
Other languages
English (en)
Chinese (zh)
Other versions
CN102470105A (zh
Inventor
诺姆·伊曼纽尔
摩西·纽曼
沙洛莫·巴拉克
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Polypid Ltd
Original Assignee
Polypid Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Polypid Ltd filed Critical Polypid Ltd
Priority to CN201510441212.8A priority Critical patent/CN105126179B/zh
Publication of CN102470105A publication Critical patent/CN102470105A/zh
Application granted granted Critical
Publication of CN102470105B publication Critical patent/CN102470105B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/65—Tetracyclines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L24/00—Surgical adhesives or cements; Adhesives for colostomy devices
    • A61L24/001—Use of materials characterised by their function or physical properties
    • A61L24/0015—Medicaments; Biocides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/28—Materials for coating prostheses
    • A61L27/34—Macromolecular materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L27/54—Biologically active materials, e.g. therapeutic substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/08—Materials for coatings
    • A61L31/10—Macromolecular materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L31/16—Biologically active materials, e.g. therapeutic substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
    • A61L2300/22—Lipids, fatty acids, e.g. prostaglandins, oils, fats, waxes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/404—Biocides, antimicrobial agents, antiseptic agents
    • A61L2300/406—Antibiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/416—Anti-neoplastic or anti-proliferative or anti-restenosis or anti-angiogenic agents, e.g. paclitaxel, sirolimus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/60—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a special physical form
    • A61L2300/602—Type of release, e.g. controlled, sustained, slow

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Surgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Transplantation (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Biophysics (AREA)
  • Materials Engineering (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Prostheses (AREA)
  • Materials For Medical Uses (AREA)
CN201080034537.XA 2009-07-14 2010-07-14 持续释放药物载体组合物 Active CN102470105B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201510441212.8A CN105126179B (zh) 2009-07-14 2010-07-14 持续释放药物载体组合物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US22528909P 2009-07-14 2009-07-14
US61/225,289 2009-07-14
PCT/IL2010/000563 WO2011007353A1 (en) 2009-07-14 2010-07-14 Sustained-release drug carrier composition

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201510441212.8A Division CN105126179B (zh) 2009-07-14 2010-07-14 持续释放药物载体组合物

Publications (2)

Publication Number Publication Date
CN102470105A CN102470105A (zh) 2012-05-23
CN102470105B true CN102470105B (zh) 2015-07-29

Family

ID=43448999

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201080034537.XA Active CN102470105B (zh) 2009-07-14 2010-07-14 持续释放药物载体组合物
CN201510441212.8A Active CN105126179B (zh) 2009-07-14 2010-07-14 持续释放药物载体组合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201510441212.8A Active CN105126179B (zh) 2009-07-14 2010-07-14 持续释放药物载体组合物

Country Status (9)

Country Link
US (2) US8992979B2 (https=)
EP (1) EP2453877B1 (https=)
JP (1) JP5738856B2 (https=)
CN (2) CN102470105B (https=)
AU (1) AU2010272167B2 (https=)
CA (1) CA2767973C (https=)
ES (1) ES2732149T3 (https=)
IN (1) IN2012DN00570A (https=)
WO (1) WO2011007353A1 (https=)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2299953B1 (en) 2008-07-14 2017-04-12 Polypid Ltd. Sustained-release drug carrier composition
EP2525778B1 (en) 2010-01-19 2018-08-01 Polypid Ltd. Sustained-release nucleic acid matrix compositions
US20140271861A1 (en) * 2011-07-27 2014-09-18 Polypid Ltd. Matrix compositions for controlled release of peptide and polypeptide molecules
US10433892B2 (en) * 2012-03-27 2019-10-08 National University Corporation Nagoya University Three-dimensional structure produced from a material containing polyhydroxyalkanoate, kit for preparation of bone filler, and intramedullary rod
ES2802025T3 (es) * 2012-08-02 2021-01-15 Polypid Ltd Composiciones y métodos para el tratamiento de huecos óseos y fracturas abiertas
CA2885334C (en) * 2012-11-14 2016-03-08 Orthopaedic Innovation Centre Inc. Antimicrobial articles produced by additive manufacturing
US9775853B2 (en) 2013-03-15 2017-10-03 Biomet Manufacturing, Llc. Hemostatic compositions and methods
TW201618783A (zh) 2014-08-07 2016-06-01 艾森塔製藥公司 以布魯頓(Bruton)氏酪胺酸激酶(BTK)佔據和BTK再合成速率為基礎之治療癌症、免疫和自體免疫疾病及發炎性疾病之方法
JP6526400B2 (ja) * 2014-09-11 2019-06-05 サンスター株式会社 口腔用組成物
WO2016051322A1 (en) * 2014-10-02 2016-04-07 Polypid Ltd. Methods for the treatment of peri-implantitis
US20170246112A1 (en) * 2014-10-02 2017-08-31 Polypid Ltd. Compositions and methods for the treatment and prophylaxis of surgical site infections
US10792477B2 (en) 2016-02-08 2020-10-06 Orbusneich Medical Pte. Ltd. Drug eluting balloon
JP7027319B2 (ja) * 2016-02-08 2022-03-01 オーバスネイチ・メディカル・プライベート・リミテッド 薬剤溶出性バルーン
CN106146761A (zh) * 2016-06-03 2016-11-23 西北大学 一种两亲性多功能聚合物及其制备的纳米胶束和应用
EP3582756A1 (en) * 2017-02-16 2019-12-25 Yeda Research and Development Co., Ltd. Liposomic drug-delivery vehicles
KR20260007295A (ko) 2018-05-24 2026-01-13 셀라니즈 이브이에이 퍼포먼스 폴리머스 엘엘씨 거대 분자 약물 화합물의 지속적인 방출을 위한 이식가능 장치
EP3803866A4 (en) 2018-05-24 2022-03-16 Nureva Inc. METHOD, APPARATUS, AND COMPUTER READABLE MATERIALS FOR MANAGING SEMI-CONSTANT (PERSISTENT) SOUND SOURCES IN MICROPHONE CATCH/HOME AREAS
MX2020012459A (es) 2018-05-24 2021-04-28 Celanese Eva Performance Polymers Llc Dispositivo implantable para liberacion sostenida de un compuesto de farmaco macromolecular.
JP7662204B2 (ja) * 2019-07-03 2025-04-15 アトッサ・セラピューティクス・インコーポレイテッド エンドキシフェンの徐放性組成物
CA3166413C (en) 2021-02-01 2024-04-09 Alon Green Systems and methods of calibrating a range measurement system
CN113081482B (zh) * 2021-04-23 2024-02-27 柏为（武汉）医疗科技股份有限公司 一种中耳防粘连膜及其制备方法
BR112023022439A2 (pt) 2021-04-26 2023-12-26 Celanese Eva Performance Polymers Llc Dispositivo implantável para liberação sustentada de um composto de fármaco macromolecular
CN113702647B (zh) * 2021-08-31 2024-03-15 普十生物科技(北京)有限公司 人生长分化因子15即时检测试剂盒、其制备方法及其应用

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040018327A1 (en) * 2001-09-28 2004-01-29 David Wynn Delayed release dosage forms
US20060188537A1 (en) * 2005-02-22 2006-08-24 Lamba-Kohli Nina M Generation of antimicrobial surfaces using dendrimer biocides
US20070280991A1 (en) * 2006-06-05 2007-12-06 Thierry Glauser Coatings for implantable medical devices for controlled release of a hydrophilic drug and a hydrophobic drug
US20080085263A1 (en) * 2004-06-04 2008-04-10 Krister Thuresson Liquid Depot Formulations
US20080119494A1 (en) * 2004-02-17 2008-05-22 Young Janel E Drug-enhanced adhesion prevention

Family Cites Families (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4522803A (en) 1983-02-04 1985-06-11 The Liposome Company, Inc. Stable plurilamellar vesicles, their preparation and use
US4882167A (en) 1983-05-31 1989-11-21 Jang Choong Gook Dry direct compression compositions for controlled release dosage forms
US4578384A (en) 1984-02-15 1986-03-25 The United States Of America As Represented By The Secretary Of The Army Polylactic-polyglycolic acids combined with an acidic phospholipid-lysozyme complex for healing osseous tissue
JPS6163613A (ja) 1984-09-04 1986-04-01 Mitsui Toatsu Chem Inc 顆粒状に調整された徐放性製剤
US5043166A (en) 1987-01-09 1991-08-27 Hadasit Medical Research, Inc. Liposome/anthraquinone drug composition and method
IL91664A (en) 1988-09-28 1993-05-13 Yissum Res Dev Co Ammonium transmembrane gradient system for efficient loading of liposomes with amphipathic drugs and their controlled release
JP3233402B2 (ja) 1989-11-13 2001-11-26 サイオス ノバ インコーポレイテッド 物質の制御送達用のリポスフェア
US6120805A (en) 1990-04-06 2000-09-19 Rhone-Poulenc Rorer Sa Microspheres, process for their preparation and their use
US5922340A (en) 1992-09-10 1999-07-13 Children's Medical Center Corporation High load formulations and methods for providing prolonged local anesthesia
US6180134B1 (en) 1993-03-23 2001-01-30 Sequus Pharmaceuticals, Inc. Enhanced ciruclation effector composition and method
EP0804249A2 (en) 1994-03-15 1997-11-05 Brown University Research Foundation Polymeric gene delivery system
US6156337A (en) 1994-07-08 2000-12-05 Opperbas Holding B.V. Method for high loading of vesicles with biopolymeric substances
US6333021B1 (en) 1994-11-22 2001-12-25 Bracco Research S.A. Microcapsules, method of making and their use
US6040295A (en) 1995-01-13 2000-03-21 Genemedicine, Inc. Formulated nucleic acid compositions and methods of administering the same for gene therapy
US5919480A (en) 1996-06-24 1999-07-06 Yissum Research Development Company Of The Hebrew University Of Jerusalem Liposomal influenza vaccine composition and method
US5837221A (en) 1996-07-29 1998-11-17 Acusphere, Inc. Polymer-lipid microencapsulated gases for use as imaging agents
WO1998007412A1 (en) 1996-08-21 1998-02-26 Alkermes Controlled Therapeutics, Inc. Controlled release microparticles with a hydrophobic material
ES2289188T3 (es) 1996-09-11 2008-02-01 Bristol-Myers Squibb Medical Imaging, Inc. Procedimiento para la obtencion de imagenes para el diagnostico usando un agente de contraste y un vasodilatador.
US6048551A (en) 1997-03-27 2000-04-11 Hilfinger; John M. Microsphere encapsulation of gene transfer vectors
EP1009390A4 (en) 1997-07-02 2004-05-06 Euro Celtique Sa LONG-EFFECT ANESTHESIA INJECTED IN JOINT AND BODY SPACES
US6287587B2 (en) 1997-07-15 2001-09-11 Takeda Chemical Industries, Ltd. Process for producing sustained-release preparation by in-water drying
US6787132B1 (en) 1997-12-04 2004-09-07 Yissum Research Development Company Of The Hebrew University Of Jerusalem Combined chemo-immunotherapy with liposomal drugs and cytokines
US6593294B1 (en) 1998-04-27 2003-07-15 Opperbas Holding B.V. Pharmaceutical composition comprising Factor VIII and neutral liposomes
US6423345B2 (en) 1998-04-30 2002-07-23 Acusphere, Inc. Matrices formed of polymer and hydrophobic compounds for use in drug delivery
IL140899A0 (en) 1998-07-17 2002-02-10 Skyepharma Inc Lipid/polymer containing pharmaceutical compositions and processes for the preparation thereof
IL140892A0 (en) 1998-08-12 2002-02-10 Yissum Res Dev Co Liposomal bupivacaine compositions prepared using an ammonium sulfate gradient
US6153217A (en) 1999-01-22 2000-11-28 Biodelivery Sciences, Inc. Nanocochleate formulations, process of preparation and method of delivery of pharmaceutical agents
US6083482A (en) 1999-05-11 2000-07-04 Icn Pharmaceuticals, Inc. Conformationally locked nucleosides and oligonucleotides
AU5624400A (en) 1999-06-18 2001-01-09 Collaborative Group, Ltd., The Hyaluronic acid film and matrix for sustained gene transfer
DE10001172A1 (de) 2000-01-13 2001-07-26 Max Planck Gesellschaft Templatieren von Feststoffpartikeln mit Polymermultischichten
US6967028B2 (en) 2000-07-31 2005-11-22 Mainelab Prolonged release microspheres for injectable administration
IL155204A0 (en) * 2000-10-02 2003-11-23 Arizeke Pharmaceuticals Inc Compositions and methods for the transport of biologically active agents across cellular barriers
FI20010540A0 (fi) 2001-03-16 2001-03-16 Yli Urpo Antti Komposiitti pehmyt- ja kovakudosvammojen korjaamiseksi ja mainitun komposiitin käyttö
TWI226249B (en) 2001-12-19 2005-01-11 Ind Tech Res Inst Biodegradable composite matrix for enhancing angiogenesis
WO2003097805A2 (en) 2002-05-15 2003-11-27 California Pacific Medical Center Delivery of nucleic acid-like compounds
US20040062778A1 (en) * 2002-09-26 2004-04-01 Adi Shefer Surface dissolution and/or bulk erosion controlled release compositions and devices
EP1596767B1 (en) * 2003-02-12 2018-10-03 Syncera, Inc. Random and non-random alkylene oxide polymer alloy compositions
GB0305941D0 (en) 2003-03-14 2003-04-23 Camurus Ab Composition
KR101293002B1 (ko) 2003-04-10 2013-08-02 데이진 가부시키가이샤 허니콤 구조를 갖는 생분해성 필름
US20040247624A1 (en) * 2003-06-05 2004-12-09 Unger Evan Charles Methods of making pharmaceutical formulations for the delivery of drugs having low aqueous solubility
US20060188573A1 (en) 2003-06-10 2006-08-24 Anna Imberg Composite materials and particles
US20050249697A1 (en) 2003-09-24 2005-11-10 Uhrich Kathryn E Compositions and methods for the inhibition of bone growth and resorption
EP1693075B1 (en) 2003-11-21 2012-10-03 Teijin Limited Substrate for tissue regeneration
US20050191344A1 (en) 2004-01-15 2005-09-01 Samuel Zalipsky Liposome composition for delivery of therapeutic agents
US7744644B2 (en) 2004-03-19 2010-06-29 Boston Scientific Scimed, Inc. Medical articles having regions with polyelectrolyte multilayer coatings for regulating drug release
DE102004025495A1 (de) * 2004-05-21 2005-12-15 Dr. Suwelack Skin & Health Care Ag Verfahren zur Herstellung von Alginat-haltigen porösen Formkörpern
JP2008502690A (ja) * 2004-06-15 2008-01-31 アンドリュー シァン チェン， リン脂質組成物ならびにその調製方法および使用方法
CA2578709C (en) 2004-06-17 2010-06-15 Virun, Inc. Compositions comprising a mucoadhesive protein and an active principle for mucosal delivery of said agents
JP2008507585A (ja) 2004-07-26 2008-03-13 コセリックス インク 微粒子製剤を用いて吸入したイロプロストによる肺高血圧症の治療
US20080095849A1 (en) 2005-04-25 2008-04-24 Amgen Inc. Peptide sustained release compositions and uses thereof
US20070141134A1 (en) 2005-12-16 2007-06-21 Kosak Matthew K Shielded micelles for polynucleotide delivery
US20090318355A1 (en) 2006-02-15 2009-12-24 Chen Thomas T Compositions and methods for promoting tissue repair and wound healing
CA2648099C (en) 2006-03-31 2012-05-29 The Brigham And Women's Hospital, Inc System for targeted delivery of therapeutic agents
CA2656179A1 (en) * 2006-06-21 2007-12-27 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for joining non-conjoined lumens
CN101209243B (zh) * 2006-12-29 2010-12-08 石药集团中奇制药技术（石家庄）有限公司 一种脂质体药物及其制备方法
KR101521989B1 (ko) * 2007-03-02 2015-05-28 테이카 세이야쿠 가부시키가이샤 경피흡수 의약조성물, 의약조성물 저장유닛 및 이것을 이용하는 경피흡수제제
WO2008124634A1 (en) 2007-04-04 2008-10-16 Massachusetts Institute Of Technology Polymer-encapsulated reverse micelles
WO2009006311A2 (en) * 2007-06-29 2009-01-08 Wisconsin Alumni Research Foundation Structuring effect of cholesterol in peg-phospholipid micelles, drug delivery of amphotericin b, and combination antifungals
US20090110713A1 (en) 2007-10-31 2009-04-30 Florencia Lim Biodegradable polymeric materials providing controlled release of hydrophobic drugs from implantable devices
AU2008325122A1 (en) 2007-11-09 2009-05-14 Northeastern University Self-assembling micelle-like nanoparticles for systemic gene delivery
WO2009110939A2 (en) 2007-12-10 2009-09-11 Massachusetts Institute Of Technology Drug delivery system for pharmaceuticals and radiation
US8128983B2 (en) 2008-04-11 2012-03-06 Abbott Cardiovascular Systems Inc. Coating comprising poly(ethylene glycol)-poly(lactide-glycolide-caprolactone) interpenetrating network
CA2721333C (en) 2008-04-15 2020-12-01 Protiva Biotherapeutics, Inc. Novel lipid formulations for nucleic acid delivery
EP2299953B1 (en) 2008-07-14 2017-04-12 Polypid Ltd. Sustained-release drug carrier composition
WO2010078517A2 (en) 2008-12-31 2010-07-08 Sirnaomics, Inc. Compositions and methods using sirna molecules and sirna cocktails for the treatment of breast cancer
CA2762095A1 (en) 2009-05-16 2010-11-25 Kunyuan Cui Compositions comprising cationic amphiphiles and colipids for delivering therapeutic molecules
EP2525778B1 (en) 2010-01-19 2018-08-01 Polypid Ltd. Sustained-release nucleic acid matrix compositions
IN2014DN05640A (https=) * 2012-01-10 2015-04-03 Elevance Renewable Sciences

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040018327A1 (en) * 2001-09-28 2004-01-29 David Wynn Delayed release dosage forms
US20080119494A1 (en) * 2004-02-17 2008-05-22 Young Janel E Drug-enhanced adhesion prevention
US20080085263A1 (en) * 2004-06-04 2008-04-10 Krister Thuresson Liquid Depot Formulations
US20060188537A1 (en) * 2005-02-22 2006-08-24 Lamba-Kohli Nina M Generation of antimicrobial surfaces using dendrimer biocides
US20070280991A1 (en) * 2006-06-05 2007-12-06 Thierry Glauser Coatings for implantable medical devices for controlled release of a hydrophilic drug and a hydrophobic drug

Also Published As

Publication number Publication date
WO2011007353A1 (en) 2011-01-20
IN2012DN00570A (https=) 2015-06-12
US20150174073A1 (en) 2015-06-25
CN105126179A (zh) 2015-12-09
ES2732149T3 (es) 2019-11-20
CN105126179B (zh) 2018-09-25
JP2012533334A (ja) 2012-12-27
CA2767973A1 (en) 2011-01-20
EP2453877A4 (en) 2013-05-29
US8992979B2 (en) 2015-03-31
US20120114756A1 (en) 2012-05-10
CN102470105A (zh) 2012-05-23
US10463617B2 (en) 2019-11-05
JP5738856B2 (ja) 2015-06-24
AU2010272167B2 (en) 2016-11-17
EP2453877A1 (en) 2012-05-23
EP2453877B1 (en) 2019-05-08
AU2010272167A1 (en) 2012-02-02
CA2767973C (en) 2019-06-18

Similar Documents

Publication Publication Date Title
CN102470105B (zh) 持续释放药物载体组合物
US10682412B2 (en) Sustained-release drug carrier composition
HK1205960B (en) Sustained-release drug carrier composition
IL210437A (en) The drug carries a drug for sustained release
HK1161069B (en) Sustained-release drug carrier composition
HK1161069A (en) Sustained-release drug carrier composition

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant